XOMA Royalty Corp. (XOMA) is a Biotechnology company in the Healthcare sector, currently trading at $40.13. It has a SharesGrow Score of 69/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of XOMA = $14.46 (-64% from the current price, the stock appears overvalued). Analyst consensus target is XOMA = $68 (+70.1% upside).
Valuation: XOMA trades at a trailing Price-to-Earnings (P/E) of 22 (S&P 500 average ~25).
Financials: revenue is $52M, +186.9%/yr average growth. Net income is $32M, growing at +85.6%/yr. Net profit margin is 60.8% (strong). Gross margin is 94.3% (-4.1 pp trend).
Balance sheet: total debt is $132M against $104M equity (Debt-to-Equity (D/E) ratio 1.27, moderate). Current ratio is 3.37 (strong liquidity). Debt-to-assets is 48.2%. Total assets: $273M.
Analyst outlook: 6 / 10 analysts rate XOMA as buy (60%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 92/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 50/100 (Partial), Moat 41/100 (Fail), Future 73/100 (Pass), Income 100/100 (Pass).
